Adverse drug reaction profile of daily regimen antituberculosis treatment

K. N. Hari Sankar, Kevin Roch, Doyce Jom, Dhanya S. Palappallil, Prabitha Panattil, Rajani K. Sankaranarayanan

Department of Pharmacology, Government Medical College, ADR Monitoring Centre, Government Medical College, NTEP Unit, Government Medical College, Kottayam, Kerala, India

Abstract

Objectives: The objective was to estimate the proportion of adverse drug reactions (ADRs) to daily regimen antituberculosis treatment (ATT) among the ADRs received in the ADR monitoring center (AMC) of the institution and to describe its pattern.

Materials and Methods: This was a descriptive study conducted in the Department of Pharmacology of a Government Medical College in Central Kerala and the period under study was October 2017–June 2020. The data on ADR were entered into a structured pro forma and data were analyzed using SPSS for Windows Version 16.0 (SPSS Inc., Chicago, USA).

Results: Of the 643 ADRs, 98 (15.24%) were suspected to be due to the daily regimen of ATT. The most common organ system affected was hepatobiliary 46 (46.9%) namely hepatitis in 35 and asymptomatic elevated liver enzymes in 11 followed by eye with 26 reports of decreased vision. In 96 (97.95%), the suspected ADR had probable causality and in 2 (2.04%) it was possible. Seventy-seven (78.6%) ADR reports were serious as well as moderate-level 4b in severity and 57 (58.16%) were probably preventable. The mean days of onset of ADR after starting the ATT regimen were 56.40 ± 58.29 days (range 1–180). Decrease in vision with a mean duration of 125.23 ± 55.46 days had the longest latency in onset among all the ADRs.

Conclusions: Of all the ADRs reported to AMC 15.24% were due to the daily regimen of ATT. Hepatitis was the most common ADR encountered followed by decrease in vision. The majority of the ADRs were probable in causality, serious, moderate-level 4b in severity, and probably preventable.

Keywords: Adverse drug reaction, antituberculosis treatment, daily regimen

INTRODUCTION

Worldwide TB is one of the top 10 causes of death and a total of 1.5 million people died of TB in 2018. Among the 8 countries that account for two-thirds of the total cases worldwide India leads the count.[3] Apart from the fatality due to the disease, the morbidity, and mortality of this disease is partly linked to the adverse drug reactions (ADRs) to the antituberculosis treatment (ATT).[3] To reduce resistance, decrease the dose required and adverse effects, combination chemotherapy with the first-line ATT recommended by the WHO namely Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), and Streptomycin (S)
are the mainstay of TB treatment.\[5\] The National Strategic Plan of India 2017–2025 builds on the accomplishment and erudition of the previous plans and is expected to transcend the steps required to eliminate TB in India by the year 2025 with robust active surveillance.\[4\] The technical and operational guidelines for tuberculosis (TB) control in 2016 have switched on daily fixed drug combination regimen for all TB patients from October 30, 2017 throughout India instead of thrice-weekly intermittent regimen.\[3\] In December 2018, the Technical Expert Group decided that all TB patients will be initiated on standard first line anti TB regimen (2HRZE/4HRE), thus lowering the category of streptomycin to a supplemental drug.\[6\]

Adverse events due to drug-sensitive as well as resistant TB treatment are one of the most important reasons for treatment interruption and nonadherence. To attain the 2025 goal of complete elimination, we have to ensure prompt referral and management of ADRs. The importance of the study lies in the sparse data available on ADRs with daily regimen of ATT compared to the thrice-weekly regimen in the Indian population. This study was done to estimate the proportion of ADRs due to the daily regimen of ATT among the ADRs reported to the ADR monitoring center (AMC) of the institution as well as to describe the characteristics of the ADR.

**MATERIALS AND METHODS**

This was a descriptive study done from July 2019 to June 2020 at the Department of Pharmacology, Government Medical College, Kottayam. The period under study was October 2017 to June 2020. The institution was approved as an AMC under the Pharmacovigilance Programme of India (PvPI) in 2012 with access to vigiflow. The AMC collects, communicate, and disseminates ADR data by linking with hospitals as well as practitioners and also provides expertise for assessing causality and severity of ADRs using standard algorithms and rating scales. The ADRs are reported in Suspected ADR (sADR) reporting forms. All ADRs reported to the AMC formed the sample population. The data which were received as a part of the PvPI from the inpatient departments of the institution, various hospitals, and the National Tuberculosis Eradication Programme (NTEP) unit of the institution during the period under study were scrutinized for ADRS following daily ATT regimen and were included in the study. The study was initiated after getting clearance from the Institutional Review Board of GMC, Kottayam (IRB No 106/2018 dated December 7, 2018). The data were entered into a structured pro forma. The drugs and organ systems affected were classified based on the therapeutic classification and the WHO-Adverse Reaction Terminology, respectively. Causality was assessed by WHO-UMC scale as well as Naranjo’s algorithm.\[7\] Severity and preventability of the ADRs were assessed by modified Hartwig and Siegel scale and Schumock Thornton scale, respectively.\[8\] Seriousness of the reaction was categorized according to the Food and Drug Administration criteria.\[9\] Predictability was determined by classifying the ADRs as Type A (Augmented) and Type B (Bizarre).\[10\] Data were analyzed using SPSS for Windows Version 16.0 (SPSS Inc., Chicago, USA). The continuous variables such as age and number of systems involved were expressed as mean ± standard deviation. Categorical variables such as gender, suspected drug, systems involved, a temporal relation of ADR, type of ADR, predictability, preventability, severity, causality, and seriousness were expressed as frequencies and percentages.

**RESULTS**

Out of the 643 ADRs reported to the AMC of the institution during the period under study, 98 (15.24%) were suspected to be due to the daily regimen of ATT. Of the 98 ADRs, 12 (12.2%) were reported in 2017, 32 (32.7%) in 2018, 33 (33.7%) in 2019, and 21 (21.4%) in 2020. The age range was 16–84 years. The mean age of persons who developed ADR to ATT was 51.64 ± 16.07 years and the male:female ratio was 1.33:1. Table 1 summarizes the clinical profile of patients who developed ADR to ATT.

As shown in Table 2, the most common organ system affected was hepatobiliary 46 (46.9%) namely hepatitis in 35 and asymptomatic elevated liver enzymes in 11. The mean total bilirubin was 4.10 ± 4.87 mg/dl, direct bilirubin was 2.27 ± 2.80 mg/dl, serum glutamic-oxaloacetic transaminase (ALT) was 29.45 ± 18.36 IU/l, and alkaline phosphatase (ALP) was 111.25 ± 69.77 IU/l. As expected, a significant increase in liver enzymes was observed in 100% of patients who developed jaundice. The mean serum creatinine was 1.21 ± 0.87 mg/dl, serum urea was 54.48 ± 52.41 mg/dl, serum uric acid was 11.73 ± 6.34 mg/dl, and serum lactic dehydrogenase (LDH) was 300.25 ± 224.87 IU/l.

**Table 1: Clinical profile of patients with adverse drug reaction to antituberculosis treatment**

| Clinical profile | n=98, n (%) |
|------------------|------------|
| Gender           |            |
| Male             | 56 (57.1)  |
| Female           | 42 (42.9)  |
| Age group (years)|            |
| 15–45            | 30 (30.6)  |
| 46–75            | 65 (66.3)  |
| >75              | 3 (3.1)    |
| TB               |            |
| Pulmonary        | 90 (91.8)  |
| Extrapulmonary-abdominal | 2 (2) |
| Extrapulmonary-lymph node | 5 (5.1) |
| Extrapulmonary-spine | 1 (1)   |
| Comorbidity      |            |
| Diabetes mellitus| 1 (1)      |
| Chronic kidney disease | 5 (5.1) |
| Nil              | 92 (93.9)  |
| Treatment        |            |
| Daily regimen-FDC| 98 (100)   |

TB = Tuberculosis, FDC = Fixed-dose combination
transaminase 356.92 ± 497.73 IU/L, serum glutamic pyruvic transaminase 253.85 ± 267.28 IU/L from the data available from the ADRs with hepatobiliary dysfunction \((n = 35)\). The second-most common affected organ system was eye and the ADR was the decreased vision (26.5%).

As shown in Figure 1, majority of the patients were managed with supportive therapy. There was no mortality reported due to ATT during the period under study and all patients were recovering at the time of reporting of ADR. The WHO-Causality assessment showed that out of the 98 cases, in 96 (97.95%) the suspected ADR was probable, and in 2 (2.04%), it was possible. Of the 98 ADRs, 77 (78.6%) were serious and resulted in hospitalization or caused prolonged hospitalization, 21 (21.4%) were not serious. Twenty (20.4%) ADRs were mild-level 2, 1 was moderate-level 4a, and 77 (78.6%) were moderate-level 4b in severity according to Hartwig and Siegel scale. Fifteen (15.30%) were definitely preventable, 26 (26.5%) were not preventable and 57 (58.16%) were probably preventable ADRs according to modified Schumock and Thornton scale. All the ADRs were type B(Bizzare). The mean days of onset of ADR after starting the ATT regimen were 56.40 ± 58.29 days (range 1–180). Figure 2 summarizes the temporal relation of ADR. Decrease in vision with a mean duration of 125.23 ± 55.46 days had the longest latency in onset among all the ADRs.

**DISCUSSION**

The WHO defined ADR in 1972 as “A response to a drug which is noxious and unintended and occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function.”[11] Iftikhar and Sarwar in a review article stated that fixed drug combinations are cost-effective, reduce the pill burden, and have logistical advantages, however, it also has several disadvantages such as poor bioavailability, enzyme level elevation, difficulty in dose adjustments, and ADRs.[12] A meta-analysis of five randomized controlled trials found that, four drug fixed-combination therapy did not have a significant overall incidence of adverse effects.[13] Resende and Santos-Neto state that the major determinants of adverse reactions to ATT are the doses, the time of the day at which the drugs are administered, age above 40 years, nutritional status in terms of loss of body weight >15%, alcohol consumption >101 ml, N-acetyltransferase status, hyponatremia, hypoalbuminemia, and co-infection with HIV.[14]

Previous studies have shown that the overall incidence of ADRs caused by anti-TB therapy ranges from 5.1% to 83.5%.[15] In this study, the proportion of ADRs due to ATT was 15.25%. Age-group most affected was 46–75 years (66.3%). Previous studies state that the frequency of adverse reactions increases in a progressive and direct form in relation to age.[16,17] The male:female ratio of patients reported to have ADR was 1.33:1 in this study. Studies elsewhere in contrast to our study found that the incidence of ADR to ATT was more in females as compared to males.[18,19] Piparva et al., reported a higher

| Organ system | n=98, n (%) | ADR | n=98, n (%) | Suspected drugs in the FDC |
|--------------|-------------|-----|-------------|----------------------------|
| Electrolyte  | 1 (1)       | Hyponatremia | 1 (1) | All ATT |
| Eye disorders| 26 (26.5)   | Decreased vision | 26 (26.5) | Ethambutol |
| Gastrointestinal | 5 (5.1) | Epigastric pain | 1 (1) | All ATT |
|               |             | Vomiting    | 3 (3.1)   |               |
|               |             | Gastritis   | 1 (1)     |               |
| Hematological | 2 (2)       | Thrombocytopenia | 2 (2) | Rifampicin, INH |
| Hepatobiliary | 46 (46.9)   | Hepatitis   | 35 (25.7) | INH, rifampicin, pyrazinamide |
| Kidney        | 1 (1)       | Acute kidney injury | 1 (1) | Streptomycin |
| Respiratory   | 1 (1)       | Pneumothorax | 1 (1) | All ATT |
| Skin and appendages | 16 (16.3) | Rash       | 2 (2)   | All ATT |
|               |             | Itching     | 13 (13.3) |               |
|               |             | Exfoliative dermatitis | 1 (1) |               |

FDC=Fixed-dose combination, ADR=Adverse drug reaction, ATT=Antituberculosis treatment
incidence of ADR to multidrug-resistant TB regimen in males and attributed it to increased awareness of health and care seeking tendency of males.\textsuperscript{[20]}

The most common organ system affected was the hepatobiliary system (46.9\%) with 35 ADRs of hepatitis and 11 of asymptomatic elevated liver enzymes. Studies show that the risk of hepatotoxicity in patients from India is higher than those reported in the West (11.5\% versus 4.3\%).\textsuperscript{[21]} The common drugs causing hepatotoxicity are isoniazid, pyrazinamide, and rifampicin. The risk of toxicity of ATT becomes higher when aspartate transferase (AST) $>$3 times the upper level of normal in the presence of symptoms or $>$5 times the upper limit of normal in the absence of symptoms. Toxicity of mild level occurs if AST and alanine transferase is $<$5 times the upper limit of normal, moderate if rise by 5–10 times and if $>$10 times it is severe. The drugs have to be stopped and reintroduced in such a manner that the least likely causative agent should be reintroduced first.\textsuperscript{[12]} In patients with hepatitis FDC was replaced with ethambutol, streptomycin, and levofloxacin at the time of reporting of the ADR. Literature shows that high alcohol intake, female gender, older age, intake of other hepatotoxic drugs, poor nutritional status, preexisting liver disease, advanced disease, and acetylator status are risk factors for hepatitis.\textsuperscript{[19]} The mean duration of onset of asymptomatic elevated liver enzymes was 27.36 ± 34.87 (range 3–125) days and that of hepatitis was 37.06 ± 36.76 (range 1–145) days. In studies done elsewhere, hepatobiliary system was the most common organ system affected with mean duration of onset of liver dysfunction 17 (range 12–68) in one and 53 (range 28–60) days in other.\textsuperscript{[10,22]}

The proportion of visual impairment in this study is very high (26.5\%) compared to those in previous studies with Directly Observed Treatment Strategy which have reported a very low incidence ranging from 0.2\% to 1\%.$^{[17,19,23]}$ Ethambutol optic neuritis is dose related and is characterized with painless loss of central vision and cecocentral scotomas. This causes reduction in visual field, visual acuity and loss of red green discrimination.$^{[23,24]}$ Though reversible after stoppage of drug there are several reports of permanent damage.\textsuperscript{[23]} The mean duration of onset of visual impairment in this study was 125.23 ± 55.46 (range 4–180) days as compared to 46 (range 34–72) days in another.\textsuperscript{[19]} ADRs related to skin and appendages (16.3\%) such as itching, exfoliative dermatitis, and rash accounted for the third most common system in this study. In a Brazilian study, it was noted that in patients receiving RHEZ-FDC ADRs related to skin and appendages was the most common.$^{[23]}$

The possible ADRs were Pneumothorax and Hyponatremia reported to our AMC by the NTEP unit of the institution. The causality assessment committee assigned it as possible because there was temporal relation of ATT with the event and it could also be explained by the disease. Khan et al., stated that Pneumothorax, especially in miliary TB, can usually develop during the treatment with ATT.\textsuperscript{[26]} Choudhary et al., have reported the occurrence of pneumothorax after 5 days of start of ATT.$^{[27]}$ In this study, pneumothorax occurred 17 days after the initiation of ATT and hyponatremia occurred after 24 days. Jafari et al. found that there was no significant correlation between anti-TB medications and hyponatremia.$^{[28]}$ Lv et al. found that the majority of the ADRs (53.1\%) were probable in their study which is in line with this study.$^{[22]}$

Of the 98 ADRs, 77 (78.6\%) were serious and were moderate-level 4b in severity (Hartwig and Siegel Scale), 57 (58.16\%) were probably preventable (Schumock Thornton scale). All the ADRs were type B-Bizzare ADRs. In the study by Lv et al., 92.3\% ADRs were non-serious.$^{[22]}$ Yee et al. stated that serious ADRs to ATT was common, and resulted in substantial health-care services utilization, as well as prolongation of therapy.$^{[17]}$ In the study by Sinha et al., most of the ADRs were mild (73.24\%) and only 15.59\% were severe reactions.$^{[18]}$ Krishnamurthy et al. states that the most important determinants of a treatment outcome of drug-resistant TB are incidence and characteristics of ADR during the treatment which may be applicable to drug sensitive TB as well.$^{[29]}$
Limitations of this study are that only data reported to the AMC of the institution were included. There could have been a delay in reporting ADRs so the days of onset of ADR may actually reflect the time the ADRs were found and not the exact time it had happened.

CONCLUSIONS

Of all the ADRs reported to AMC 15.24% were due to the daily regimen of ATT. Hepatitis was the most common ADR encountered followed by decrease in vision. The majority of the ADRs were probable in causality, serious, moderate-level 4b in severity and probably preventable.

Acknowledgment

The authors would like to thank the services of the PvPI and all the clinicians who reported the ADRs to our AMC.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. World Health Organisation. Tuberculosis. Available from: https://www.who.int/health-topics/tuberculosis#tab=tab_1. [Last accessed on 2020 Jul 13].
2. Gholami K, Kamali E, Hajabdollahbaghi M, Shalviri G. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract (Granada) 2006;4:134-8.
3. Kurniawati F, Sulaiman SA, Gillani SW. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. Int J Pharm Life Sci 2012;3:13312-8.
4. India TB Report; 2018. Available from: https://tbcindia.gov.in/showfile.php?id=3314. [Last accessed on 2020 Jun 05].
5. Technical and Operational Guidelines for Tuberculosis Control in India 2016. Available from: https://tbcindia.gov.in/index1.php?lang =1&level=2&sublinkid=4573&lid=3177. [Last accessed on 2020 Jun 05].
6. Sachdeva KS. Ministry of Health and Family Welfare. Letter D O No-28015/27/2012-TB (Part II); Dated December 18, 2018.
7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
8. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
9. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
10. US Food and Drug Administration. Reporting Serious Problems to FDA. U.S. FDA. Available from: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm. [Last accessed on 2020 Jul 13].
11. World Health Organisation. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/

12. Ifthikhar S, Sarwar MR. Potential disadvantages associated with treatment of active tuberculosis using fixed-dose combination: A review of literature. J Basic Clin Pharma 2017;8:131-6.
13. Lima GC, Silva EV, Magalhães PQ, Naves JS. Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: A systematic review and meta-analysis. Braz J Microbiol 2017;48:198-207.
14. Resende LS, Santos-Neto ET. Risk factors associated with adverse reactions to antituberculosis drugs. J Bras Pneumol 2015;41:77-89.
15. Maciel EL, Guidoni LM, Favero JI, Hadad DJ, Molino LP, Jonhson JL, et al. Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. J Bras Pneumol 2010;36:232-8.
16. Chung-Delgado K, Revilla-Montag A, Guileen-Bravo S, Velze-Segovia E, Soria-Montoya A, Nuñez-Garbin A, et al. Factors associated with anti-tuberculosis medication adverse effects: A case-control study in Lima, Peru. PLoS One 2011;6:e27610.
17. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7.
18. Sinha K, Marak ITR, Singh WA. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. J Assoc Chest Phys 2013;1:50-3.
19. Farazi A, Sofian M, Jabbarial M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014;2014:412893.
20. Piparva KG, Jansari G, Singh AP. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot. Perspect Clin Res 2018;9:165-9.
21. Sharma SK, Balamurugun A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-9.
22. Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: A prospective study. PLoS One 2013;8:e65037.
23. Song W, Si S. The rare ethambutol-induced optic neuropathy: A case-report and literature review. Medicine 2017;96:e5889.
24. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 2009;93:1251-4.
25. Arriaga MB, Torres NMC, Araujo NCN, Caldas SCC, Andrade BB, Netto EM. Impact of the change in the antituberculosis regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study. PLoS One 2019;14:e0227101.
26. Khan NA, Akhtar J, Baneen U, Shameem M, Ahmed Z, Bhargava R. Recurrent pneumothorax: A rare complication of miliary tuberculosis. N Am J Med Sci 2011;3:428-30.
27. Choudhari OK, Spalgais S, Ojha UC, Murar AK, Verma AK. Miliary tuberculosis with bilateral recurrent pneumothoraces. Actaocyto 2017;4:192-4.
28. Jonaidi Jafari N, Izadi M, Sarrafzadeh F, Heidari A, Ranjbar R, Saburi A. Hyponatremia due to pulmonary tuberculosis: Review of 200 cases. Nephrourol Mon 2013;5:687-91.
29. Krishnamurthy S. Drug-resistant tuberculosis – A ticking time bomb! Perspect Clin Res 2018;9:153-4.